|Bid||280.44 x 0|
|Ask||280.54 x 0|
|Day's range||276.00 - 280.85|
|52-week range||225.53 - 342.75|
|Beta (5Y monthly)||0.22|
|PE ratio (TTM)||63.52|
|Earnings date||19 Aug 2020|
|Forward dividend & yield||2.93 (1.04%)|
|Ex-dividend date||11 Mar 2020|
|1y target est||151.95|
When you buy a stock there is always a possibility that it could drop 100%. But when you pick a company that is really...
LEXINGTON, Mass. and AMSTERDAM, June 24, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that uniQure and CSL Behring have entered into a licensing agreement providing CSL Behring with exclusive global rights to etranacogene dezaparvovec, uniQure’s investigational gene therapy for patients with hemophilia B. Etranacogene dezaparvovec consists of an AAV5 viral vector carrying a gene cassette with the patent-protected Padua variant of Factor IX (FIX-Padua). Under the terms of the agreement, uniQure will receive a $450 million upfront cash payment and be eligible to receive up to $1.6 billion in payments based on regulatory and commercial milestones.
Thermo Fisher (TMO), through its alliance with CSL, expands Pharma Services arm to meet the rising demand for biologic therapies.